Diaryl ether β 2 adrenergic receptor agonists

Details Diaryl ether β 2 adrenergic receptor agonists Diaryl ether β 2 adrenergic receptor agonists

2007-11-19

2010-02-16

Chu, Yong (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S312000, C514S314000, C514S651000

Reexamination Certificate

active

07662815

ABSTRACT:
The invention provides novel β2adrenergic receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with β2adrenergic receptor activity, and processes and intermediates useful for preparing such compounds.

REFERENCES:
patent: 4894219 (1990-01-01), Baker et al.
patent: 4992474 (1991-02-01), Skidmore et al.
patent: 5064863 (1991-11-01), Alig et al.
patent: 5977154 (1999-11-01), Bell et al.
patent: 6346532 (2002-02-01), Maruyama et al.
patent: 6436914 (2002-08-01), Sher et al.
patent: 6541669 (2003-04-01), Moran et al.
patent: 6576793 (2003-06-01), Moran et al.
patent: 6653323 (2003-11-01), Moran et al.
patent: 6670376 (2003-12-01), Moran et al.
patent: 6949568 (2005-09-01), Moran et al.
patent: 7037938 (2006-05-01), Hattori et al.
patent: 7125892 (2006-10-01), Moran et al.
patent: 7399863 (2008-07-01), Linsell et al.
patent: 7402673 (2008-07-01), Linsell
patent: 2002/0022625 (2002-02-01), Walland et al.
patent: 2002/0143034 (2002-10-01), Taniguchi et al.
patent: 2003/0229058 (2003-12-01), Moran et al.
patent: 2004/0242890 (2004-12-01), Coe et al.
patent: 2005/0159448 (2005-07-01), McKinnell et al.
patent: 2008/0039495 (2008-02-01), Linsell
patent: 0 147 719 (1985-07-01), None
patent: 1 463 219 (1977-02-01), None
patent: WO 00/40560 (2000-07-01), None
patent: WO 01/07026 (2001-02-01), None
patent: WO 01/35947 (2001-05-01), None
patent: WO 01/36413 (2001-05-01), None
patent: WO 01/42193 (2001-06-01), None
patent: WO 02/00622 (2002-01-01), None
patent: WO 02/06276 (2002-01-01), None
patent: WO 02/38544 (2002-05-01), None
patent: WO 03/024439 (2003-03-01), None
patent: WO 2004/002939 (2004-01-01), None
patent: WO 2004/016578 (2004-02-01), None
patent: WO 2004/016601 (2004-02-01), None
patent: WO 2004016601 (2004-02-01), None
Bompart et al., “Synthesis of new β-blockers analogs of bevantolol”, Annales Pharmaceutiques Francaises, Volume Date 1984, 42(6), pp. 537-545 (1985) (In French with English abstract).
Bompart et al., “Synthesis of new β-blockers analogous of the bevantolol or the alprenolol”, Annales Pharmaceutiques Francaises, Volume Date 1987, 45(5), pp. 379-387 (1988) (In French with English abstract).
Deyrup et al., “Structure-affinity profile of 8-hydroxycarbostyril-based agonists that dissociate slowly from the Beta2-adrenoceptor”, Naunyn-Schmiedeberg's Arch Pharmacol (1999) 359:168-177.
Fotsch et al., “Synthesis and Structure-Activity Relationships of Trisubstituted Phenyl Urea Derivatives as Neuropeptide Y5 Receptor antagonists”, J. Med. Chem., (2001), 44:2344-2356.
Isogaya et al., “Binding Pockets of the β1- and β2-Adrenergic Receptors for Subtype-Selective Agonists”, Molecular Pharmacology, vol. 56, pp. 875-885 (1999).
Milecki et al., “Carbostyril Derivatives Having Potent β-Adrenergic Agonist Properties”, J. Med. Chem, (1987), 30, 1563-1566.
Shuker et al., “The Application of High-Throughput Synthesis and Purification to the Preparation of Ethanolamines”, Tetrahedron Letters, (1997), 38(35):6149-6152.
Yokoi et al., “The Development of a Radioimmunoassay for Formoterol”, Life Sciences, (1983) vol. 33, No. 17, pp. 1665-1672.
Yoshizaki et al., “Sympathomimetic Amines Having a Carbostyril Nucleus”, J. Med. Chem., (1976), vol. 19, No. 9, pp. 1138-1142.
Alikhani et al., “Long-chain formoterol analogues: an investigation into the effect of Increasing amino-substituent chain length on the β2-adrenoceptor activity”, Bioorganic & Medicinal Chemistry Letters, 14, pp. 4705-4710 (2004).

Affiliated with

Also associated with

Rating

Diaryl ether β 2 adrenergic receptor agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Diaryl ether β 2 adrenergic receptor agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diaryl ether β 2 adrenergic receptor agonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4224203